Hubei Guangji Pharmaceutical Co Ltd
Hubei Guangji Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical raw materials, pharmaceutical preparations, and feed additives in China and internationally. It also exports its products. The company was founded in 1969 and is based in Wuxue, China.
Hubei Guangji Pharmaceutical Co Ltd (000952) - Total Assets
Latest total assets as of September 2025: CN¥2.58 Billion CNY
Based on the latest financial reports, Hubei Guangji Pharmaceutical Co Ltd (000952) holds total assets worth CN¥2.58 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hubei Guangji Pharmaceutical Co Ltd - Total Assets Trend (1996–2024)
This chart illustrates how Hubei Guangji Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hubei Guangji Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Hubei Guangji Pharmaceutical Co Ltd's total assets of CN¥2.58 Billion consist of 33.0% current assets and 67.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 11.0% |
| Accounts Receivable | CN¥229.83 Million | 8.2% |
| Inventory | CN¥322.03 Million | 11.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥239.62 Million | 8.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (1996–2024)
This chart illustrates how Hubei Guangji Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hubei Guangji Pharmaceutical Co Ltd's current assets represent 33.0% of total assets in 2024, a decrease from 44.6% in 1996.
- Cash Position: Cash and equivalents constituted 11.0% of total assets in 2024, up from 1.1% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, a decrease from 15.0% in 1996.
- Asset Diversification: The largest asset category is inventory at 11.5% of total assets.
Hubei Guangji Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Hubei Guangji Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
PINK:NVSEF
|
USA | $115.49 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $133.96 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367
|
China | CN¥1.52 Billion |
Hubei Guangji Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Hubei Guangji Pharmaceutical Co Ltd generates 0.23x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Hubei Guangji Pharmaceutical Co Ltd is currently not profitable relative to its asset base.
Hubei Guangji Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.67 | 0.98 | 1.52 |
| Quick Ratio | 0.41 | 0.67 | 1.17 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-403.36 Million | CN¥ -18.78 Million | CN¥ 241.65 Million |
Hubei Guangji Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Hubei Guangji Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.89 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | -7.8% |
| Total Assets | CN¥2.79 Billion |
| Market Capitalization | $234.89 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hubei Guangji Pharmaceutical Co Ltd's assets below their book value (0.08 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Hubei Guangji Pharmaceutical Co Ltd's assets decreased by 7.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hubei Guangji Pharmaceutical Co Ltd (1996–2024)
The table below shows the annual total assets of Hubei Guangji Pharmaceutical Co Ltd from 1996 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.79 Billion | -7.79% |
| 2023-12-31 | CN¥3.03 Billion | +22.70% |
| 2022-12-31 | CN¥2.47 Billion | +20.51% |
| 2021-12-31 | CN¥2.05 Billion | +3.51% |
| 2020-12-31 | CN¥1.98 Billion | +12.05% |
| 2019-12-31 | CN¥1.77 Billion | +4.32% |
| 2018-12-31 | CN¥1.69 Billion | +3.13% |
| 2017-12-31 | CN¥1.64 Billion | +0.49% |
| 2016-12-31 | CN¥1.63 Billion | +0.81% |
| 2015-12-31 | CN¥1.62 Billion | +2.42% |
| 2014-12-31 | CN¥1.58 Billion | +1.97% |
| 2013-12-31 | CN¥1.55 Billion | -0.27% |
| 2012-12-31 | CN¥1.56 Billion | +3.27% |
| 2011-12-31 | CN¥1.51 Billion | +8.83% |
| 2010-12-31 | CN¥1.38 Billion | +6.18% |
| 2009-12-31 | CN¥1.30 Billion | +8.02% |
| 2008-12-31 | CN¥1.21 Billion | +20.86% |
| 2007-12-31 | CN¥998.76 Million | +27.23% |
| 2006-12-31 | CN¥785.02 Million | -11.04% |
| 2005-12-31 | CN¥882.44 Million | -3.24% |
| 2004-12-31 | CN¥911.95 Million | +5.19% |
| 2003-12-31 | CN¥866.94 Million | +5.74% |
| 2002-12-31 | CN¥819.91 Million | +7.62% |
| 2001-12-31 | CN¥761.83 Million | +12.66% |
| 2000-12-31 | CN¥676.22 Million | +4.23% |
| 1999-12-31 | CN¥648.78 Million | +71.29% |
| 1998-12-31 | CN¥378.76 Million | +13.72% |
| 1997-12-31 | CN¥333.05 Million | +36.00% |
| 1996-12-31 | CN¥244.89 Million | -- |